Similarly, Shavit et al. also showed reduction in systolic blood pressure (166 ± 14 to 153 ± 10 mm Hg, P < 0.05) in HD patients with the mineralocorticoid receptor antagonist eplerenone[21]. This evidence concerns the gene NR3C2 and Huntington disease.